TargetBeta
INHBA
inhibin subunit beta A · Inhibin subunits
2 programs in company-led studies act on INHBA, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| sotaterceptrule | Merck | phase 4 | 268 running | – | ChEMBL |
| garetosmabrule | Regeneron Pharmaceuticals | phase 3 | 92 running | – | ChEMBL |
Conditions their studies are in
- Anemia, 1 program
- beta-Thalassemia, 1 program
- Hypertension, Pulmonary, 1 program
- Multiple Myeloma, 1 program
- Myositis Ossificans, 1 program
- Myositis, Inclusion Body, 1 program
- Obesity, 1 program
- Ossification, Heterotopic, 1 program
- Pulmonary Arterial Hypertension, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 21, 2028sotatercept · Merck · phase 4 · NCT07899905
- Jul 8, 2030garetosmab · Regeneron Pharmaceuticals · phase 3 · NCT07559513
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.